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As the pandemic has been unfolding, reports have emerged of a relatively high incidence of
coagulopathy and thromboembolic events in connection with COVID-19 infections. Raised
awareness surrounding this issue, and appropriate antithrombotic prophylaxis and
treatment, are therefore important for this group of patients.
The COVID-19 pandemic has dominated the medical debate in recent months, and has
impacted all aspects of society (1). SARS-CoV-2 is a virus of the Corona group which
primarily attacks the respiratory epithelium and can result in acute respiratory distress
syndrome. In extreme cases, the outcome may be fatal (2). Recent reports have also shown
that thromboembolic events are frequent in COVID-19 patients and contribute to increased
mortality and morbidity (3). This has also been registered in Norway (4). Arterial
thromboembolism is serious, but is much rarer among COVID-19 patients than venous
thromboembolism (5). This article provides a brief overview of the association between
COVID-19 and venous thromboembolic disease. Given our brief experience of COVID-19, few
large-scale clinical studies have been conducted. This article is therefore based on non-
systematic literature reviews, recently published recommendations and guidelines, initial
experience and discussions among the medical professionals who are treating this group of
patients. Based on available knowledge at this stage of the pandemic, we can now provide
general prophylaxis and treatment recommendations, with a focus on venous
thromboembolic events.
Pathophysiology
We have known for a long time that there is an association between the activation of an
inflammatory response and the activation of the coagulation system. This is often referred
to as thrombo-inflammation or immunothrombosis (6, 7), and patients with an infectious
disease will therefore have an elevated risk of thromboembolic events (7). Increased
production of proinflammatory multi-effect cytokines is probably an important link (6, 7).
The inflammatory effects of cytokines also cause activation of and damage to endothelial
cells, which further strengthens procoagulatory mechanisms (6, 8). The extensive
inflammation seen in patients with COVID-19 infection is reflected in high levels of
inflammatory markers such as CRP, fibrinogen and various cytokines – interleukin 6
appears to be particularly important (9). SARS-CoV-2 does not itself appear to have direct
procoagulatory effects, but more recent data suggest that the virus does not only attack the
respiratory epithelium, but can also attack the endothelium, especially in the lungs (10).
The reason is probably that SARS-CoV-2 uses a receptor for angiotensin-converting enzyme 2
(ACE2) as a gateway to the cells (11). This receptor is found on the epithelium of the
respiratory tract and the gastrointestinal tract, as well as in the endothelium. This is
additional to the factors that increase the risk of severe COVID-19 disease as well as venous
thromboembolism in at-risk patients, the most important of which appear to be age,
obesity and kidney disease (12, 13). Finally, there are factors such as immobilisation due to
disease or hospitalisation and central venous catheters, which in themselves increase the
thromboembolic tendency.
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Incidence, diagnostics and risk stratification
It is difficult based on existing data to estimate reliable incidence figures for venous
thromboembolism in cases of COVID-19 infection. However, the risk of events appears to
increase with the severity of the disease and with other coexisting predisposing factors
(14–18). Furthermore, it also seems to be clear that the incidence of thrombotic events is
higher for COVID-19 infections than for other viral infectious diseases (5, 18).
Epidemiological data are largely available only from hospitalised patients, and we have no
indication of the real incidence of venous thromboembolism among all COVID-19 patients,
including ambulant patients and elderly care home residents. A cohort study from a large
Dutch hospital showed that the cumulative incidence rates of venous thromboembolism
after 7, 14 and 21 days of hospitalisation were 16 %, 33 % and 41 % respectively (16). It is also
worth noting that thromboembolic complications have been reported in patients who are
already receiving prophylactic anticoagulation (5, 14, 18). Studies have also indicated that
biochemical markers can be used as diagnostic and prognostic markers – especially
elevated D-dimer levels (19, 20). If there are biochemical signs of coagulopathy, greater
clinical attention should be given to a potential coexisting thromboembolism. Several
studies have also shown a clear association between developing coagulopathy and
mortality risk (19, 21). Some COVID-19 patients develop disseminated intravascular
coagulation (DIC) a few days into the disease, and these patients clearly have a poorer
prognosis (22, 23). We must stress that the increased mortality may well be due to a more
generalised inflammation (including the development of a cytokine storm) rather than the
effect of coagulation (9, 24). It is also worth noting that COVID-19 patients generally appear
to have a low risk of haemorrhaging (3).
Pulmonary embolism can be difficult to diagnose. Pulmonary emboli are easily missed,
since severe COVID-19 disease in itself results in hypoxaemia and respiratory failure (17). The
thrombotic tendency and thromboembolic events may occur at a relatively late stage of the
disease (4).
The diagnostic procedures do not in principle differ from any other diagnosis of pulmonary
embolism, for which a CT scan under pulmonary embolism protocol is the standard.
However, this may be harder to achieve with COVID-19 patients, as it may be difficult to
move those who are most severely affected, and the heightened risk of transmission will add
to the complications. In some cases, treatment should therefore be initiated on the basis of
a strong suspicion, such as changed haemodynamics and oxygenation, and
echocardiography signs that the right side of the heart is under acute stress. Several studies
have tested the use of coagulation parameters as potential prognostic and diagnostic
markers. Given that D-dimer values are often elevated due to general inflammation, it is
difficult to use this test specifically to diagnose pulmonary embolism, but it has been
pointed out that a clear increase of values should generally give cause to suspect coexisting
thromboembolism in patients with COVID-19 (3, 20).
Prophylaxis and treatment
Given our short experience of COVID-19, general recommendations have been based on
initial reports and knowledge acquired to date (3, 21, 23). International guidelines have now
appeared which provide a more systematic summary of recommended prophylaxis and
treatment of thromboembolic complications in cases of COVID-19 (25). On this basis, Table 1
outlines our proposals for how to manage such patients. Thromboprophylaxis is not
normally recommended for ambulant patients who receive treatment for relatively mild
symptoms of COVID-19. Ambulant patients who are at a higher risk of thromboembolic
events, for instance due to a history of thrombosis, obesity (BMI > 30) and active cancer
disease, can be considered for prophylaxis with low-molecular-weight heparin on an
individual basis. All hospitalised patients with COVID-19 should be assessed for standard
prophylaxis with low-molecular-weight heparin if there are no contraindications, such as a
known tendency to haemorrhage or a clear thrombocytopenia (thrombocytes < 25 ∙ 109/l).
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Table 1
The authors’ proposals for prophylaxis and anticoagulation in cases of COVID-19 disease,
updated in May 2020. The recommendations are generally based on international, national
and local anticoagulation guidelines and discussions among Norwegian medical experts (3,
4, 21, 23, 25).
Status Proposed anticoagulation treatment
Prophylaxis for ambulant
patients
Not generally indicated, but a prophylactic dose of
low-molecular-weight heparin may be considered for
patients with a history of venous thrombosis, active
cancer disease or obesity (BMI > 30 kg/m2).
Prophylaxis for hospitalised
patients
Standard prophylactic dose of low-molecular-weight
heparin for all patients unless there is a significantly
elevated risk of haemorrhage.
Prophylaxis for hospitalised
patients in intensive care
Increased prophylactic dose of low-molecular-weight
heparin (50 % of therapeutic dose or double the
prophylactic dose).
Continuation for patients already
on anticoagulant drugs (atrial
fibrillation, history of venous
thrombosis, mechanical heart
valve)
Continue the patient’s current anticoagulation
medication; consider changing to therapeutic dose of
low-molecular-weight heparin.
Treatment in cases of suspected
venous thromboembolism
Therapeutic dose of low-molecular-weight heparin
until diagnosis is verified.
Treatment in cases of verified
venous thromboembolism
Therapeutic dose of low-molecular-weight heparin,
consider changing to peroral treatment on discharge.
Treatment to continue for at least three months.
The data are less unequivocal when it comes to increasing the prophylactic dose.
International reports have shown a high incidence of venous thrombosis even if standard
prophylaxis is administered (14, 18). This suggests that the thromboprophylaxis should be
increased for patients with severe COVID-19 disease, particularly patients who are treated in
an intensive care unit, including those on a ventilator (3, 18, 23). It is difficult to estimate the
correct dose, but one common approach is to administer 50 % of the therapeutic dose or
double the standard thromboprophylactic dose (3, 4, 21, 23, 25). Whichever of the two
approaches is adopted, the resultant dose tends to be roughly the same. Verified
coagulopathy, defined as elevated D-dimer values, is a factor which further indicates
increased prophylaxis (20). When pulmonary embolism or deep vein thrombosis is
determined, a therapeutic dose of low-molecular-weight heparin should be administered.
The total treatment period should be at least three months from the time of discharge when
the patient has full mobilisation, unless other factors suggest a longer treatment period.
Changing to peroral treatment should be considered on discharge. For patients who are
already on anticoagulants when COVID-19 infection is determined, the treatment should
continue. We should be alert to any potential interaction between anticoagulation and
experimental treatments for COVID-19 infection, if this is relevant (23). Changing to
parenteral treatment should be considered if peroral treatment is impossible, or in order to
ensure stable anticoagulation in cases of gastrointestinal symptoms, which can be relatively
common in cases of COVID-19 infection. When changing from peroral to parenteral
treatment, therapeutic doses of low-molecular-weight heparin should be considered.
Conclusion
COVID-19 disease appears to be associated with a particularly high risk of venous
thromboembolic complications, especially in severe cases. There are still no unequivocal
data for what constitutes appropriate prophylaxis and treatment, and for the time being
recommendations are largely based on short patient series and initial experiences.
Nevertheless, it appears to be clear that liberal use of thromboprophylaxis is
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recommendable, and it is probable that the same applies for increased prophylaxis in
certain patients. Norwegian doctors who treat this patient group should be aware of these
issues.
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